ArticleEpidemiology and infection2019
Epidemiology, risk factors and outcomes of
Article in Epidemiology and infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.Medical mycology · 2024Pooled it
- Emerging antifungal strategies against Candida albicans using metal-organic frameworks and novel therapeutics: Opportunities and challenges.Journal of food and drug analysis · 2026Review
- In vitro evaluation of Curcuma longa extract for antifungal, antibiofilm, and synergistic activity against Candida spp.Scientific reports · 2026Article
- Epidemiology, risk factors, and mortality of Candida bloodstream infection in Yulin, China: a 7-year retrospective study.BMC infectious diseases · 2026Article
- Can Time to Blood Culture Positivity Influence the Treatment Strategy in Candidemia Management?Journal of clinical practice and research · 2026Article
- Candidemia in a tertiary hospital in Southern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Influence of local denture-related factors on the inflammatory marker levels in patients with denture stomatitis.BMC oral health · 2025Article
- Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC infectious diseases · 2025Article
- Epidemiology risk factors and antifungal resistance patterns ofFrontiers in microbiology · 2025Article
- Prevalence, Mortality, Antifungal Resistance, and Risk Factors of Candidemia Among Cancer Patients in a Single Center of Southern China: A 10-Year Retrospective Study.Journal of tropical medicine · 2025Article
- Denture microbiome shift and changes of salivary inflammatory markers following insertion of 3D printed removable partial PMMA denture: a pilot study.BMC oral health · 2024Article
- The role ofJournal of medical microbiology · 2024Article
- Epidemiology and Risk Factors of Candidemia a 8-Year Retrospective Study from a Teaching Hospital in China.Infection and drug resistance · 2024Article
- Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.Current microbiology · 2023Article
- Six-Year Retrospective Analysis of Epidemiology, Risk Factors, and Antifungal Susceptibilities of Candidiasis from a Tertiary Care Hospital in South China.Microbiology spectrum · 2023Article
- The Epidemiology and Clinical Characteristics of Fungemia in a Tertiary Hospital in Southern China: A 6-Year Retrospective Study.Mycopathologia · 2023Article
- Characterization and susceptibility of non-albicansFrontiers in public health · 2023Observational
- Biofilm: The invisible culprit in catheter-induced candidemia.AIMS microbiology · 2023Review
- Pseudolaric Acid A: A Promising Antifungal Agent Against Prevalent Non-Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the clinical characteristics, risk factors and outcomes of adult patients with candidaemia caused by C. albicans vs. non-albicans Candida spp. (NAC). All adult hospitalised cases of candidaemia (2012-2017) at a tertiary hospital in Shenyang were included in the retrospective study, and a total of 180 episodes were analysed. C. parapsilosis was the most frequently isolated species (38.3%), followed by C. albicans (35.6%), C. glabrata (13.9%), C. tropicalis (10%) and others (2.2%). As initial antifungal therapy, 75.0%, 3.9%, 5.6% and 2.2% of patients received fluconazole, caspofungin, micafungin and voriconazole, respectively. Multivariate analyses revealed that total parenteral nutrition was associated with an increased risk of NAC bloodstream infections (BSI) (OR 2.535, 95% CI (1.066-6.026)) vs. C. albicans BSI. Additionally, the presence of a urinary catheter was associated with an increased risk of C. albicans BSI (OR 2.295 (1.129-4.666)) vs. NAC BSI. Moreover, ICU stay (OR 4.013 (1.476-10.906)), renal failure (OR 3.24 (1.084-9.683)), thrombocytopaenia (OR 7.171 (2.152-23.892)) and C. albicans (OR 3.629 (1.352-9.743)) were independent risk factors for candidaemia-related 30-day mortality, while recent cancer surgery was associated with reduced mortality risk (OR 26.479 (2.550-274.918)). All these factors may provide useful information to select initial empirical antifungal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.